Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En randomiseret, international undersøgelse for at vurdere sikkerheden ved iTind sammenlignet med UroLift (MT-08)

25. september 2026 opdateret af: Olympus Corporation of the Americas

En post-market, prospektiv, randomiseret, kontrolleret, multicenter international undersøgelse for at vurdere sikkerheden af ​​den midlertidigt implanterede Nitinol-enhed (iTind) sammenlignet med UroLift®-systemet hos personer med symptomatisk benign prostatahyperplasi (BPH)

The study objective is to evaluate the efficacy and safety of the iTind device compared to UroLift.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Both iTind and UroLift are minimally invasive treatment options for relieving lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). The iTind device is a temporary, self-expanding nitinol implant that remains in place for 5 to 7 days to reshape the prostatic urethra through localized ischemic pressure and tissue remodeling. In contrast, the UroLift system involves the permanent placement of transprostatic implants that retract the enlarged lateral lobes of the prostate to widen the urethral lumen.

This study is designed to directly compare the safety and effectiveness of the iTind device versus the UroLift system in treating LUTS due to BPH.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

256

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Dunfermline, Det Forenede Kongerige, KY12 0SU
        • Rekruttering
        • Queen Margaret Hospital
        • Ledende efterforsker:
          • Feras Al Jaafari, MD
        • Kontakt:
      • London, Det Forenede Kongerige, GU16 7UJ
        • Rekruttering
        • Frimley Park Hospital
        • Ledende efterforsker:
          • Neil Barber, MD
        • Kontakt:
      • Norwich, Det Forenede Kongerige, NR4 7UY
        • Rekruttering
        • Norfolk & Norwich University Hospital
        • Ledende efterforsker:
          • Mark Rochester, MD
        • Kontakt:
    • Middlesex
      • Isleworth, Middlesex, Det Forenede Kongerige, TW7 6AF
        • Rekruttering
        • Chelsea and Westminster Hospital
        • Ledende efterforsker:
          • Samuel Bishara, MD
        • Kontakt:
    • Arizona
      • Phoenix, Arizona, Forenede Stater, 85054
        • Rekruttering
        • Mayo Clinic Arizona
        • Ledende efterforsker:
          • Mitchell Humphreys, MD
        • Kontakt:
      • Tucson, Arizona, Forenede Stater, 85704
        • Afsluttet
        • Arizona Urology Specialists
    • California
      • Fresno, California, Forenede Stater, 93720
        • Rekruttering
        • Urology Associates of Central California
        • Ledende efterforsker:
          • William Schiff, MD
        • Kontakt:
      • Sacramento, California, Forenede Stater, 95823
        • Rekruttering
        • Golden State Urology
        • Ledende efterforsker:
          • Prithipal Sethi, MD
        • Kontakt:
    • Illinois
      • Evanston, Illinois, Forenede Stater, 60201
        • Afsluttet
        • NorthShore University Health System Research Institute
    • Louisiana
      • New Orleans, Louisiana, Forenede Stater, 70119
        • Aktiv, ikke rekrutterende
        • Southeast Louisiana Veterans Health Care System
    • Minnesota
      • Woodbury, Minnesota, Forenede Stater, 55125
        • Trukket tilbage
        • Minnesota Urology
    • Nebraska
      • Omaha, Nebraska, Forenede Stater, 68124
        • Rekruttering
        • The Urology Center
        • Ledende efterforsker:
          • Sida Niu, MD
        • Kontakt:
    • Nevada
      • Las Vegas, Nevada, Forenede Stater, 89121
        • Rekruttering
        • Pacific West Urology
        • Kontakt:
        • Ledende efterforsker:
          • Joel Abbott, MD
    • New York
      • Syosset, New York, Forenede Stater, 11791
        • Rekruttering
        • Feinstein Institutes for Medical Research / Northwell Health
        • Ledende efterforsker:
          • Bilal Chughtai, MD
        • Kontakt:
    • Tennessee
      • Germantown, Tennessee, Forenede Stater, 38138
        • Rekruttering
        • The Conrad Pearson Clinic
        • Ledende efterforsker:
          • Adam Stewart, MD
        • Kontakt:
    • Texas
      • Austin, Texas, Forenede Stater, 78705
        • Rekruttering
        • Midtown Urology Associates
        • Ledende efterforsker:
          • Tyler McClintock, MD
        • Kontakt:
      • Houston, Texas, Forenede Stater, 77027
        • Rekruttering
        • Houston Metro Urology
        • Kontakt:
        • Ledende efterforsker:
          • Mark Sutton, MD
      • San Antonio, Texas, Forenede Stater, 78240
        • Rekruttering
        • The Urology Place
        • Ledende efterforsker:
          • Naveen Kella, MD
        • Kontakt:
    • Virginia
      • Alexandria, Virginia, Forenede Stater, 22311
        • Rekruttering
        • Potomac Urology Center
        • Ledende efterforsker:
          • Nilay Gandhi, MD
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

50 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Han

Beskrivelse

Inclusion Criteria:

  1. Diagnosis of lower urinary tract symptoms presumed to be secondary to benign prostatic enlargement causing bladder outlet obstruction for which treatment is recommended
  2. Willing and able to provide informed consent
  3. Males ≥ 50 years of age or older
  4. PSA < 4 ng/ml or if the PSA is 4 - 10 ng/ml, prostate cancer must be ruled out to the satisfaction of the Principal Investigator (PI) by local standard of care methods within prior 6 months
  5. Prostate volume up to 75 cc (inclusive) documented by cross-sectional imaging (TRUS, MRI, etc.). Results from standard of care imaging may be accepted up to 6 months prior to Screening
  6. International Prostate Symptom Score (IPSS) for urinary symptoms ≥ 13
  7. Maximum urinary flow rate (Qmax) of ≤ 15 mL/sec and ≥ 5 mL/sec (voided volume must be ≥ 125 mL)
  8. Willing and able to complete all study visits including questionnaires at baseline and at follow-up visits

Exclusion Criteria:

  1. History of prostate cancer or suspected, should be ruled out to the satisfaction of the PI by local standard of care methods within prior 6 months
  2. Confirmed bladder cancer within the last 2 years or currently suspected bladder cancer
  3. History of acute bacterial prostatitis within the last 2 years
  4. Median lobe obstruction of the prostate as confirmed by cross-sectional imaging
  5. PSA value > 10 ng/ml
  6. Contraindicated for iTind or UroLift as determined by the PI
  7. Neurogenic bladder and/or sphincter abnormalities due to Parkinson's disease, multiple sclerosis, cerebral vascular accident, diabetes or other neurological disorders that affect bladder function
  8. Clinically significant bladder diverticulum
  9. Diagnosed with urethral stricture, meatal stenosis, bladder neck contracture, rectal disease, artificial urinary sphincter, incompetent sphincter, urinary incontinence due to incompetent sphincter
  10. Prior rectal surgery (other than hemorrhoidectomy) or history of rectal disease treatment if the therapy may potentially cause injury to site (e.g., if a transrectal probe is used), pelvic radiotherapy or radical pelvic surgery, urinary diversion surgery, prostate surgery, balloon dilation, urethral stent implantation, laser prostatectomy, or any other invasive treatment to the prostate, or penile prosthesis if it may prevent insertion of the iTind or UroLift device
  11. An active urinary tract infection during randomization
  12. Clinically significant hematuria within the last 3 months or ongoing cystolithiasis
  13. Prostate volume > 75 cc
  14. Post-void residual volume (PVR) > 250 mL
  15. Actively using catheterization or unable to void naturally
  16. Unable to complete a 2-week washout period for alpha blockers prior to procedure or unable to discontinue 5ARIs or daily use of PDE5 inhibitors by the time of procedure
  17. Taking anti-platelet or anticoagulants (except low dose aspirin - 81 mg - 100 mg) within the last 7 days prior to procedure
  18. Known or suspected allergy to nickel, titanium or polyester/polypropylene

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: iTind arm

The iTind is a minimally invasive temporary implant

The iTind is implemented for 5-7 days

Aktiv komparator: UroLift

The UroLift is a minimally invasive permanent implant

UroLift is a minimally invasive procedure where permanent implants are placed in the prostate.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Difference in change of IPSS from baseline between iTind and UroLift groups at 3 months
Tidsramme: 3 months

Difference in change of IPSS from baseline between iTind and UroLift groups at 3 months

3 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Difference in change of IPSS from baseline between iTind and UroLift groups at 12 months
Tidsramme: 12 month

Difference in change of IPSS from baseline between iTind and UroLift groups at 12 months

12 month
Incidence of all intraoperative and post-operative adverse events (AEs) (i.e., related to procedure and/or device) through 3 months post-procedure.
Tidsramme: 3 month

Incidence of all intraoperative and post-operative adverse events (AEs) (i.e., related to procedure and/or device) through 3 months post-procedure.

3 month
Difference in change of IPSS from baseline between iTind and UroLift groups at 1, 6, 24, and 36 months
Tidsramme: 1, 6, 24, and 36 months

Difference in change of IPSS from baseline between iTind and UroLift groups at 1, 6, 24, and 36 months

1, 6, 24, and 36 months
Difference in change of QoL scores (SHIM, MSHQ-EjD, SF-6D) from baseline between iTind and UroLift at 1, 3, 6, 12, 24, and 36 months
Tidsramme: 1, 3, 6, 12, 24, and 36 months

Difference in change of QoL scores (SHIM, MSHQ-EjD, SF-6D) from baseline between iTind and UroLift at 1, 3, 6, 12, 24, and 36 months

1, 3, 6, 12, 24, and 36 months
Difference in rate of re-intervention between iTind and UroLift groups at 1, 3, 6, 12, 18, 24, and 36 months
Tidsramme: 1, 3, 6, 12, 18, 24, and 36 months

Difference in rate of re-intervention between iTind and UroLift groups at 1, 3, 6, 12, 18, 24, and 36 months

1, 3, 6, 12, 18, 24, and 36 months
Difference in reporting between iTind and UroLift groups at 1, 6, 12, 18, 24, and 36, months •Overall incidence of procedure and/or device related adverse events
Tidsramme: 1, 6, 12, 18, 24, and 36, months

Difference in reporting between iTind and UroLift groups at 1, 6, 12, 18, 24, and 36, months

•Overall incidence of procedure and/or device related adverse events

1, 6, 12, 18, 24, and 36, months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Neil Barber, MD, Frimley Park Hospital
  • Ledende efterforsker: Bilal Chughtai, MD, Northwell Health

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

26. september 2022

Primær færdiggørelse (Anslået)

15. juli 2027

Studieafslutning (Anslået)

31. maj 2030

Datoer for studieregistrering

Først indsendt

7. februar 2021

Først indsendt, der opfyldte QC-kriterier

14. februar 2021

Først opslået (Faktiske)

17. februar 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

29. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

25. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • MT-08

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .